Selected research
Industry Research
NGS Tumor Gene Analysis Software Industry Research Report 2026
Market perspective
The global NGS Tumor Gene Analysis Software market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the NGS Tumor Gene Analysis Software market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the NGS Tumor Gene Analysis Software market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the NGS Tumor Gene Analysis Software market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of NGS Tumor Gene Analysis Software include Roche, Illumina, Thermo Fisher Scientific, BGI Group, Novogene, Geneseeq, AmoyDx, Burning Rock Medicine and GTH.O, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global NGS Tumor Gene Analysis Software market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to NGS Tumor Gene Analysis Software.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
NGS Tumor Gene Analysis Software Market by Company
Roche
Illumina
Thermo Fisher Scientific
BGI Group
Novogene
Geneseeq
AmoyDx
Burning Rock Medicine
GTH.O
Golden Helix, Inc
Diatech Pharmacogenetics
ViennaLab Diagnostics GmbH
3D Medicines
NGS Tumor Gene Analysis Software Segment by Type
Non-Small Cell Lung Cancer
Human 6 Gene Mutations
Human 12 Gene Mutations
Other
NGS Tumor Gene Analysis Software Segment by Application
Hospitals and Health Systems
Research Institute
Other
NGS Tumor Gene Analysis Software Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS Tumor Gene Analysis Software market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NGS Tumor Gene Analysis Software and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS Tumor Gene Analysis Software.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of NGS Tumor Gene Analysis Software companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non-Small Cell Lung Cancer
- Human 6 Gene Mutations
- Human 12 Gene Mutations
- Other
Applications
- Hospitals and Health Systems
- Research Institute
- Other
Companies covered
- Roche
- Illumina
- Thermo Fisher Scientific
- BGI Group
- Novogene
- Geneseeq
- AmoyDx
- Burning Rock Medicine
- GTH.O
- Golden Helix, Inc
- Diatech Pharmacogenetics
- ViennaLab Diagnostics GmbH
- 3D Medicines
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 NGS Tumor Gene Analysis Software by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Non-Small Cell Lung Cancer
- 2.2.3 Human 6 Gene Mutations
- 2.2.4 Human 12 Gene Mutations
- 2.2.5 Other
- 2.3 NGS Tumor Gene Analysis Software by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospitals and Health Systems
- 2.3.3 Research Institute
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 NGS Tumor Gene Analysis Software Breakdown Data by Type
- 3.1 Global NGS Tumor Gene Analysis Software Historic Market Size by Type (2021-2026)
- 3.2 Global NGS Tumor Gene Analysis Software Forecasted Market Size by Type (2027-2032)
4 NGS Tumor Gene Analysis Software Breakdown Data by Application
- 4.1 Global NGS Tumor Gene Analysis Software Historic Market Size by Application (2021-2026)
- 4.2 Global NGS Tumor Gene Analysis Software Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global NGS Tumor Gene Analysis Software Market Perspective (2021-2032)
- 5.2 Global NGS Tumor Gene Analysis Software Growth Trends by Region
- 5.2.1 Global NGS Tumor Gene Analysis Software Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 NGS Tumor Gene Analysis Software Historic Market Size by Region (2021-2026)
- 5.2.3 NGS Tumor Gene Analysis Software Forecasted Market Size by Region (2027-2032)
- 5.3 NGS Tumor Gene Analysis Software Market Dynamics
- 5.3.1 NGS Tumor Gene Analysis Software Industry Trends
- 5.3.2 NGS Tumor Gene Analysis Software Market Drivers
- 5.3.3 NGS Tumor Gene Analysis Software Market Challenges
- 5.3.4 NGS Tumor Gene Analysis Software Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top NGS Tumor Gene Analysis Software Players by Revenue
- 6.1.1 Global Top NGS Tumor Gene Analysis Software Players by Revenue (2021-2026)
- 6.1.2 Global NGS Tumor Gene Analysis Software Revenue Market Share by Players (2021-2026)
- 6.2 Global NGS Tumor Gene Analysis Software Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of NGS Tumor Gene Analysis Software Head Office and Area Served
- 6.4 Global NGS Tumor Gene Analysis Software Players, Product Type & Application
- 6.5 Global NGS Tumor Gene Analysis Software Manufacturers Established Date
- 6.6 Global NGS Tumor Gene Analysis Software Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America NGS Tumor Gene Analysis Software Market Size (2021-2032)
- 7.2 North America NGS Tumor Gene Analysis Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America NGS Tumor Gene Analysis Software Market Size by Country (2021-2026)
- 7.4 North America NGS Tumor Gene Analysis Software Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe NGS Tumor Gene Analysis Software Market Size (2021-2032)
- 8.2 Europe NGS Tumor Gene Analysis Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe NGS Tumor Gene Analysis Software Market Size by Country (2021-2026)
- 8.4 Europe NGS Tumor Gene Analysis Software Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific NGS Tumor Gene Analysis Software Market Size (2021-2032)
- 9.2 Asia-Pacific NGS Tumor Gene Analysis Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific NGS Tumor Gene Analysis Software Market Size by Country (2021-2026)
- 9.4 Asia-Pacific NGS Tumor Gene Analysis Software Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America NGS Tumor Gene Analysis Software Market Size (2021-2032)
- 10.2 South America NGS Tumor Gene Analysis Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America NGS Tumor Gene Analysis Software Market Size by Country (2021-2026)
- 10.4 South America NGS Tumor Gene Analysis Software Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa NGS Tumor Gene Analysis Software Market Size (2021-2032)
- 11.2 Middle East & Africa NGS Tumor Gene Analysis Software Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa NGS Tumor Gene Analysis Software Market Size by Country (2021-2026)
- 11.4 Middle East & Africa NGS Tumor Gene Analysis Software Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.1.4 Roche NGS Tumor Gene Analysis Software Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Illumina
- 12.2.1 Illumina Company Information
- 12.2.2 Illumina Business Overview
- 12.2.3 Illumina Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.2.4 Illumina NGS Tumor Gene Analysis Software Product Portfolio
- 12.2.5 Illumina Recent Developments
- 12.3 Thermo Fisher Scientific
- 12.3.1 Thermo Fisher Scientific Company Information
- 12.3.2 Thermo Fisher Scientific Business Overview
- 12.3.3 Thermo Fisher Scientific Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.3.4 Thermo Fisher Scientific NGS Tumor Gene Analysis Software Product Portfolio
- 12.3.5 Thermo Fisher Scientific Recent Developments
- 12.4 BGI Group
- 12.4.1 BGI Group Company Information
- 12.4.2 BGI Group Business Overview
- 12.4.3 BGI Group Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.4.4 BGI Group NGS Tumor Gene Analysis Software Product Portfolio
- 12.4.5 BGI Group Recent Developments
- 12.5 Novogene
- 12.5.1 Novogene Company Information
- 12.5.2 Novogene Business Overview
- 12.5.3 Novogene Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.5.4 Novogene NGS Tumor Gene Analysis Software Product Portfolio
- 12.5.5 Novogene Recent Developments
- 12.6 Geneseeq
- 12.6.1 Geneseeq Company Information
- 12.6.2 Geneseeq Business Overview
- 12.6.3 Geneseeq Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.6.4 Geneseeq NGS Tumor Gene Analysis Software Product Portfolio
- 12.6.5 Geneseeq Recent Developments
- 12.7 AmoyDx
- 12.7.1 AmoyDx Company Information
- 12.7.2 AmoyDx Business Overview
- 12.7.3 AmoyDx Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.7.4 AmoyDx NGS Tumor Gene Analysis Software Product Portfolio
- 12.7.5 AmoyDx Recent Developments
- 12.8 Burning Rock Medicine
- 12.8.1 Burning Rock Medicine Company Information
- 12.8.2 Burning Rock Medicine Business Overview
- 12.8.3 Burning Rock Medicine Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.8.4 Burning Rock Medicine NGS Tumor Gene Analysis Software Product Portfolio
- 12.8.5 Burning Rock Medicine Recent Developments
- 12.9 GTH.O
- 12.9.1 GTH.O Company Information
- 12.9.2 GTH.O Business Overview
- 12.9.3 GTH.O Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.9.4 GTH.O NGS Tumor Gene Analysis Software Product Portfolio
- 12.9.5 GTH.O Recent Developments
- 12.10 Golden Helix, Inc
- 12.10.1 Golden Helix, Inc Company Information
- 12.10.2 Golden Helix, Inc Business Overview
- 12.10.3 Golden Helix, Inc Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.10.4 Golden Helix, Inc NGS Tumor Gene Analysis Software Product Portfolio
- 12.10.5 Golden Helix, Inc Recent Developments
- 12.11 Diatech Pharmacogenetics
- 12.11.1 Diatech Pharmacogenetics Company Information
- 12.11.2 Diatech Pharmacogenetics Business Overview
- 12.11.3 Diatech Pharmacogenetics Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.11.4 Diatech Pharmacogenetics NGS Tumor Gene Analysis Software Product Portfolio
- 12.11.5 Diatech Pharmacogenetics Recent Developments
- 12.12 ViennaLab Diagnostics GmbH
- 12.12.1 ViennaLab Diagnostics GmbH Company Information
- 12.12.2 ViennaLab Diagnostics GmbH Business Overview
- 12.12.3 ViennaLab Diagnostics GmbH Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.12.4 ViennaLab Diagnostics GmbH NGS Tumor Gene Analysis Software Product Portfolio
- 12.12.5 ViennaLab Diagnostics GmbH Recent Developments
- 12.13 3D Medicines
- 12.13.1 3D Medicines Company Information
- 12.13.2 3D Medicines Business Overview
- 12.13.3 3D Medicines Revenue in NGS Tumor Gene Analysis Software Business (2021-2026)
- 12.13.4 3D Medicines NGS Tumor Gene Analysis Software Product Portfolio
- 12.13.5 3D Medicines Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst